BlackBoxRX
 
We highly recommend enabling Javascript while using the BlackBoxRX site.

Emicizumab

Thrombotic Microangiopathy and Thromboembolism

  • Cases of thrombotic microangiopathy and thrombotic events were reported when on average a cumulative amount of >100 U/kg/24 hours of activated prothrombin complex concentrate was administered for 24 hours or more to patients receiving HEMLIBRA prophylaxis. Monitor for the development of thrombotic microangiopathy and thrombotic events if aPCC is administered. Discontinue aPCC and suspend dosing of HEMLIBRA if symptoms occur.

Patient Counseling Information

Medication Guides

Patient Medication Guide - HEMLIBRA

Package Inserts

Emicizumab

Additional Information

Updated December 2017